Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Q2 Overview Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 MillionStrong Cash position of $10.5 MillionSubmission of De Novo application to FDA...
-
4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week...
-
Dublin, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The "Clinical Medical Laboratory Services Market 2025-2029 - Strategy & Trends with Forecasts by Assay Type, Place, Product and Country, with Situation...
-
Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage...
-
Austin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allergic Conjunctivitis Market Size & Growth Analysis: “According to SNS Insider, the Allergic Conjunctivitis Market was valued at USD 2.75 billion in...
-
4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in...
-
Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Quantum Dots Market Outlook to 2029" has been added to ResearchAndMarkets.com's offering. The Global Quantum Dots Market, valued at USD 4 billion,...
-
DALLAS, July 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System and focused on medical diagnostics for faster and...
-
OSLO, Norway, July 24, 2025 (GLOBE NEWSWIRE) -- Galleon Embedded Computing (“Galleon” or “the Company”), a trusted provider of high-performance, high-quality storage solutions, rugged data recorder...
-
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...